Newton BioCapital

DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies.

NeuVasQ is developing drugs to restore blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, as well as neurodegenerative diseases such as Alzheimer's. It is based on discoveries about the molecular mechanisms that keep the blood-brain barrier intact (BBB). The BBB regulates the exchange of information between the vascular and central nervous systems (CNS). Increased BBB permeability, whether due to age or injury, plays a role in many neurological conditions by allowing harmful blood substances to enter the CNS. Many neurodegenerative disorders, such as Alzheimer's, as well as a variety of acute neurological conditions, such as stroke and epilepsy, are associated with BBB dysfunction.

DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies.

ChromaCure is engaged in the development of innovative cancer therapies, focusing on discovering first-in-class small molecule therapeutics to address unmet needs in oncology. The company is initiating a drug development program aimed at identifying new candidates that selectively and potently inhibit cancer targets. This initiative seeks to provide novel treatment options for multiple forms of cancer, either as standalone therapies or in combination with existing immunotherapy or chemotherapy approaches. Through its efforts, ChromaCure aims to enhance the therapeutic landscape for cancer patients, offering potential new solutions for various cancer types.

Synergia Medical aims at developing and commercializing next generation neurostimulation devices. It relies on a seasoned management team with extensive experience in developing implantable neurostimulators. In only three years time, the company became ISO13485 certified, created and sold an OEM external neurostimulator for a motorized amputee prosthesis arm and developed its first version of the NAOS platform. Supported by private investors and public research grants, the company has quickly grown to a team of thirteen highly skilled multidisciplinary professionals.

Dim3 develops and markets innovative clinical expert platforms and medical devices. Our solutions speed up medical decisions, enhance the life of patients and reduce healthcare costs. Now on the market, DIM3 first platform focuses on the fight against disease-related malnutrition. This is a major but silent threat that costs lives and an estimated 170 billions euros/year for Europe only.